Toward the automation of threat modeling and risk assessment in IoT systems

The Internet of Things (IoT) has recently become one of the most relevant emerging technologies in the IT landscape. IoT systems are characterized by the high heterogeneity of involved architectural components (e.g., device platforms, services, networks, architectures) and involve a multiplicity of application domains. In the IoT scenario, the identification of specific security requirements and the security design are very complex and expensive tasks, since they heavily depend on the configuration deployment actually in place and require security experts. In order to overcome these issues, we propose an approach aimed at supporting the security analysis of an IoT system by means of an almost completely automated process for threat modeling and risk assessment, which also helps identify the security controls to implement in order to mitigate existing security risks. We demonstrate the effectiveness of the approach by discussing its application to a home automation system, built on top of commercial IoT products

Planting parallel program simulation on the cloud

n/

SerpinB3 as hepatic marker of post-resective shear stress

Post-resective liver failure is a frequent complication of liver surgery and it is due to portal hyperperfusion of the remnant liver and to arterial vasoconstriction, as buffer response of the hepatic artery. In this context, splenectomy allows a reduction of portal flow and increases the survival chance in preclinical models. SerpinB3 is over-expressed in the liver in oxidative stress conditions, as a mechanism of cell defense to provide survival by apoptosis inhibition and cell proliferation. In this study, the expression of SerpinB3 was assessed as predictor of liver damage in in vivo models of major hepatic resection with or without splenectomy. Wistar male rats were divided into 4 groups: group A received 30% hepatic resection, group B > 60% resection, group C > 60% resection with splenectomy and group D sham-operated. Before and after surgery liver function tests, echo Doppler ultrasound and gene expression were assessed. Transaminase values and ammonium were significantly higher in groups that underwent major hepatic resection. Echo Doppler ultrasound showed the highest portal flow and resistance of the hepatic artery in the group with > 60% hepatectomy without splenectomy, while the association of splenectomy determined no increase in portal flow and hepatic artery resistance. Only the group of rats without splenectomy showed higher shear-stress conditions, reflected by higher levels of HO-1, Nox1 and of Serpinb3, the latter associated with an increase of IL-6. In conclusion, splenectomy controls inflammation and oxidative damage, preventing the expression of Serpinb3. Therefore, SerpinB3 can be considered as a marker of post-resective shear stress

Hypoxia up-regulates SERPINB3 through HIF-2\u3b1 in human liver cancer cells.

SERPINB3 is a cysteine-proteases inhibitor up-regulated in a significant number of cirrhotic patients carrying hepatocellular carcinoma (HCC) and recently proposed as a prognostic marker for HCC early recurrence. SERPINB3 has been reported to stimulate proliferation, inhibit apoptosis and, similar to what reported for hypoxia, to trigger epithelial-to-mesenchymal transition (EMT) and increased invasiveness in liver cancer cells. This study has investigated whether SERPINB3 expression is regulated by hypoxia-related mechanisms in liver cancer cells. Exposure of HepG2 and Huh7 cells to hypoxia up-regulated SERPINB3 transcription, protein synthesis and release in the extracellular medium. Hypoxia-dependent SERPINB3 up-regulation was selective (no change detected for SERPINB4) and operated through hypoxia inducible factor (HIF)-2\u3b1 (not HIF-1\u3b1) binding to SERPINB3 promoter, as confirmed by chromatin immuno-precipitation assay and silencing experiments employing specific siRNAs. HIF-2\u3b1-mediated SERPINB3 up-regulation under hypoxic conditions required intracellular generation of ROS. Immuno-histochemistry (IHC) and transcript analysis, performed in human HCC specimens, revealed co-localization of the two proteins in liver cancer cells and the existence of a positive correlation between HIF-2\u3b1 and SERPINB3 transcript levels, respectively. Hypoxia, through HIF-2\u3b1-dependent and redox-sensitive mechanisms, up-regulates the transcription, synthesis and release of SERPINB3, a molecule with a high oncogenic potential

Applications of quark-hadron duality in F2 structure function

Inclusive electron-proton and electron-deuteron inelastic cross sections have been measured at Jefferson Lab (JLab) in the resonance region, at large Bjorken x, up to 0.92, and four-momentum transfer squared Q2 up to 7.5 GeV2 in the experiment E00-116. These measurements are used to extend to larger x and Q2 precision, quantitative, studies of the phenomenon of quark-hadron duality. Our analysis confirms, both globally and locally, the apparent violation of quark-hadron duality previously observed at a Q2 of 3.5 GeV2 when resonance data are compared to structure function data created from CTEQ6M and MRST2004 parton distribution functions (PDFs). More importantly, our new data show that this discrepancy saturates by Q2 ~ 4 Gev2, becoming Q2 independent. This suggests only small violations of Q2 evolution by contributions from the higher-twist terms in the resonance region which is confirmed by our comparisons to ALEKHIN and ALLM97.We conclude that the unconstrained strength of the CTEQ6M and MRST2004 PDFs at large x is the major source of the disagreement between data and these parameterizations in the kinematic regime we study and that, in view of quark-hadron duality, properly averaged resonance region data could be used in global QCD fits to reduce PDF uncertainties at large x.Comment: 35 page

Transverse momentum dependence of semi-inclusive pion production

Cross sections for semi-inclusive electroproduction of charged pions ($\pi^{\pm}$) from both proton and deuteron targets were measured for $0.2<x<0.5$, $2<Q^2<4$ GeV$^2$, $0.3<z<1$, and $P_t^2<0.2$ GeV$^2$. For $P_t<0.1$ GeV, we find the azimuthal dependence to be small, as expected theoretically. For both $\pi^+$ and $\pi^-$, the $P_t$ dependence from the deuteron is found to be slightly weaker than from the proton. In the context of a simple model, this implies that the initial transverse momenta width of $d$ quarks is larger than for $u$ quarks and, contrary to expectations, the transverse momentum width of the favored fragmentation function is larger than the unfavored one.Comment: 15 pages, 4 figures. Fit form changed to include Cahn effect Minor revisions. Added one new figur

The Onset of Quark-Hadron Duality in Pion Electroproduction

A large data set of charged-pion electroproduction from both hydrogen and deuterium targets has been obtained spanning the low-energy residual-mass region. These data conclusively show the onset of the quark-hadron duality phenomenon, as predicted for high-energy hadron electroproduction. We construct several ratios from these data to exhibit the relation of this phenomenon to the high-energy factorization ansatz of electron-quark scattering and subsequent quark-to- pion production mechanisms.Comment: 11 pages, 3 figures, accepted in Phys. Rev. Lett. Tables adde

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

The use of serial serum measurements of the carbohydrate antigen 19-9 (CA19-9) to guide treatment decisions and serve as a surrogate end point in clinical trial design requires further validation. We investigated whether CA19-9 decline represents an accurate surrogate for survival and time to treatment failure (TTF) in a cohort of 76 patients with advanced pancreatic cancer receiving fixed-dose rate gemcitabine in three separate studies. Statistically significant correlations between percentage CA19-9 decline and both overall survival and TTF were found, with median survival ranging from 12.0 months for patients with the greatest degree of biomarker decline (>75%) compared with 4.3 months in those whose CA19-9 did not decline during therapy (P<0.001). Using specific thresholds, patients with ⩾25% decline in CA19-9 during treatment had significantly better outcomes than those who did not (median survival and TTF of 9.6 and 4.6 months vs 4.4 and 1.5 months; P<0.001). Similar results were seen using both 50 and 75% as cutoff points. We conclude that serial CA19-9 measurements correlate well with clinical outcomes in this patient population, and that decline in this biomarker should be entertained for possible use as a surrogate end point in clinical trials for the selection of new treatments in this disease